georgeclerk/iStock via Getty Images
Ovid Therapeutics (NASDAQ:OVID) added ~13% on Thursday after Wedbush revised its rating to Outperform from not rated, citing the neuro drug developer’s lead candidate OV329 targeted at rare and treatment-resistant forms of epilepsy and seizures.
Analyst Jay Olson’s bullish view
